search
Back to results

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

Primary Purpose

COVID-19

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
VYD222
Sponsored by
Invivyd, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for COVID-19

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All Sexes

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    August 18, 2023
    Last Updated
    August 18, 2023
    Sponsor
    Invivyd, Inc.
    Collaborators
    In Expanded Access, treating physicians are the Sponsors
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06004128
    Brief Title
    Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
    Official Title
    Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Invivyd, Inc.
    Collaborators
    In Expanded Access, treating physicians are the Sponsors

    4. Oversight

    5. Study Description

    Brief Summary
    Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    COVID-19

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    VYD222
    Intervention Description
    Monoclonal antibody

    10. Eligibility

    Sex
    All

    12. IPD Sharing Statement

    Learn more about this trial

    Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

    We'll reach out to this number within 24 hrs